Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) investors concerning the Company and its officers’ possible violations of federal securities laws.

Novo Nordisk is a healthcare company that engages in the discovery, development, manufacture and marketing of pharmaceutical products worldwide. The Company has allegedly colluded with other insulin producers to fix prices.

On August 5, 2016, Novo Nordisk disclosed disappointing earnings for the second quarter of 2016, shrinking its predictions for sales growth and reporting the loss of a contract with a large U.S. pharmacy benefit manager (“PBM”).

On this news, Novo Nordisk’s American Depositary Receipt (“ADR”) price fell over 9% on August 5, 2016.

Then, on October 28, 2016, Novo Nordisk announced its second consecutive quarter of disappointing earnings and cut its long-term profit-growth forecasts by 50%. Additionally, the Company also acknowledged receipt of a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York for information concerning Novo Nordisk’s contracts and business relationships with PBMs related to certain of the Company’s insulin products.

On this news, Novo Nordisk’s ADR price fell over 12% on October 28, 2016.

If you purchased Novo Nordisk ADRs, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.